EXHIBIT 99.2



CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO



SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of PainCare Holdings,
Inc. (the Company) on Form 10-QSB for the period ending March 31, 2003, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Mark Szporka, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



|(1) |  | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and exchange Act of 1934; and
|--- |  | -------------------------------------------------------------------------------------------------------------------------



|(2) |  | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|--- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------



|(3) |  | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report.
|--- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(4) |  | I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act rules 13a-14 and 15d-14) for the Company and have:
|--- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | i. |  | designed such disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries is made known
to us by others within those entities, particularly during the period in which this quarterly report is being prepared.
| | -- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | ii. |  | evaluated the effectiveness of the Companys disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report
(the Evaluation Date); and
| | --- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | iii. |  | presented in this quarterly report my conclusions about the effectiveness of the disclosure controls and procedures based on my evaluation as of the Evaluation Date.
| | ---- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(5) |  | I have disclosed, based on my most recent evaluation, to the Companys auditors and the audit committee of the Companys board of directors (or persons
performing the equivalent function):
|--- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | iii. |  | all significant deficiencies in the design or operation of internal controls which could adversely affect the Companys ability to record, process summarize and
report financial data and have identified for the Companys auditors any material weakness in internal controls; and
| | ---- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | iv. |  | any fraud, whether or not material, that involves management or other employees who have a significant role in the Companys internal controls.
| | --- |  | -----------------------------------------------------------------------------------------------------------------------------------------------



|(6) |  | I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
|--- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Date: April 28, 2003

/s/Mark
Szporka

Mark Szporka

Chief Financial Officer